Navigation Links
Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2014 And Announces ARRY-520 Development Strategy
Date:10/31/2013

p="name">Michael Carruthers, Chief Financial Officer, will lead the call.Conference Call InformationDate: Thursday, October 31, 2013Time:9:00 a.m. eastern timeToll-Free:(877) 261-8990Toll:(847) 619-6441Pass Code:35902809Webcast, including Replay and Conference Call Slides:  http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage oncology development company, with two wholly-owned hematology programs and two partnered MEK inhibitors in multiple pivotal trials.  ARRY-520 is a targeted KSP inhibitor being developed to treat patients with multiple myeloma and has demonstrated clinical activity as monotherapy, and in combination with both Kyprolis® (carfilzomib) and Velcade® (bortezomib).  ARRY‐614 is an oral p38/Tie2 inhibitor with a novel mechanism of action being developed to treat patients with myelodysplastic syndromes.  Both selumetinib, partnered with AstraZeneca, and MEK162, partnered with Novartis,  are being studied in several pivotal trials in a variety of solid tumors.  For more information on Array, please go to www.arraybiopharma.com.

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the timing of the announcement of the results of clinical trials for our proprietary and our partnered programs, the timing of the completion or initiation of further development of our wholly-owned and our partnered programs, expectations that events will occur that will resul
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
2. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
3. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
4. Array BioPharma Announces Proposed Public Offering Of Common Stock
5. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
6. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
7. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
10. Array BioPharma To Present At The Cowen Annual Health Care Conference
11. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Alemania, December 17, 2014 Los ... con un alto nivel de gasto en investigación y ... 2013/14 (finalizado el 30 de septiembre de 2014) ZEISS ... 4.287 millones de euros (año anterior: 4.190 millones de ... desfavorables. Las ganancias (EBIT) crecieron un 14 por ciento, ...
(Date:12/17/2014)... NEW YORK , Dec. 17, 2014 /PRNewswire-USNewswire/ ... resonance imaging (MRI), the MRI market is seeing ... cardiovascular and breast MRI scans account for the ... providing a higher resolution of images, which are creating ... resonance imaging (MRI) market is growing at a ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... PSTX) today announced that The Mount Sinai Hospital in New York City has implemented its Safety-Sponge System. , ... , , ... ... ...
... N.J. , March 15 Regado Biosciences, Inc., ... with active control agents, announced that Chris Rusconi , ... Zelenkofske , DO, FACC, Senior Vice President , Chief Medical ... on Monday, March 15, 2010 in Atlanta, ...
Cached Medicine Technology:Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 2Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 2Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 4
(Date:12/19/2014)... Wisconsin (PRWEB) December 19, 2014 After ... music performer is again returning to the stage to ... her husband for concert performances, and the successful tour ... was originally announced. , Visit Ticketability.com ... the newly-announced Detroit shows at fair prices. , Music ...
(Date:12/19/2014)... good shape seems to reduce your risk of high blood ... than 57,000 Americans, including more than 35,000 with high blood ... Those in the poorest shape had a more than 70 ... of the study, compared to a 50 percent chance for ... than 8,000 people diagnosed with high blood pressure during the ...
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
(Date:12/17/2014)... FL (PRWEB) December 17, 2014 While countless ... people do not realize the potential dangers of their purchase. ... valid prescription from a qualified doctor, but patients who buy ... the point that there is actually no real hCG present. ... States, where there are no safety standards and may contain ...
(Date:12/17/2014)... 17, 2014 HeartMath® Inc., recognized ... stress, heart rate variability (HRV), heart coherence and ... extensive HRV databases and algorithms to chipset manufacturers ... enable HeartMath’s partners to offer its HRV solutions, ... as well as its normative HRV databases and ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3
... June 24 Lightspeed Design, Inc. announces the release ... state-of-the-art capture and playback of HD 3D media. DepthQ(R) ... professional clients in corporate, entertainment, medical and industrial applications ... new DepthQ(R) family of stereoscopic software -- DepthQ(R)Capture(TM) and ...
... Dr. Marc Sarti from the University of Virginia ... to target small cancerous lung lesions that were located in extremely ... for the diagnosis and treatment for these patients was the first ... the lungs, small potential cancers are extremely difficult to access for ...
... every online purchase of new Maui Jim sunglasses results in a ... , LAHAINA, Hawaii, June 24 Effective today and extending ... Jim sunglasses from http://www.mauijim.com will ... to Unite for Sight, the preeminent non-profit group dedicated to improvement ...
... to participate in the Foundation,s Orange ... , NEW YORK, June 24 The Crohn,s & Colitis Foundation, ... from the second annual Celebrating UC Success essay contest. ... program that honors people who have found personal ways to manage ...
... Surveyed Physicians Will Increase Their Use of Carbapenems In ... from AMR and Decision Resources , , MALVERN, ... Arlington Medical Resources (AMR) and Decision Resources find ... a leading drug attribute that surveyed physicians prefer for ...
... Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - ... of recovering intellectual property (IP) rights that could provide ... Company retained a USA based IP consultant to attempt ... preferred shareholder and its corporate advisors, verily believe was ...
Cached Medicine News:Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 2Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 3Health News:Veran Medical Enables Breakthrough 4D Navigation to Cancer Lesions at University of Virginia Hospital 2Health News:Maui Jim Teams With Unite for Sight in New 'Buy One, Give One' Program to Improve Eye Health Amongst the World's Most Needy 2Health News:Maui Jim Teams With Unite for Sight in New 'Buy One, Give One' Program to Improve Eye Health Amongst the World's Most Needy 3Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 2Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 3Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 4Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 5Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 2Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 3Health News:Hard To Treat Diseases (HTDS.PK) To Regain Intellectual Property (IP) Ownership 2Health News:Hard To Treat Diseases (HTDS.PK) To Regain Intellectual Property (IP) Ownership 3
Designed to give maximum drying area while taking up minimal bench space....
Used to remove wrinkles from sections and for reorientating embedded tissue....
Compact instrument that quickly dries racks of slides using warm air....
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: